Brief: Histogen Announces Removal Of Clinical Hold By FDA For Hst-003 Ind To Initiate A Phase 1/2 Trial For Knee Cartilage Regeneration

Histogen

15/03/2021 12:58

March 15 (Reuters) - Histogen Inc  HSTO.O :
    * HISTOGEN ANNOUNCES REMOVAL OF CLINICAL HOLD BY FDA FOR
HST-003
IND TO INITIATE A PHASE 1/2 TRIAL FOR KNEE CARTILAGE
REGENERATION
    * HISTOGEN INC - ANTICIPATE INITIATING PHASE 1/2 TRIAL OF
HST-003
IN Q2 OF 2021

Source text for Eikon:  ID:nGNX6lx4gy 
Further company coverage:  HSTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))